United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) -

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine 5 mg in 1 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - nelarabine, quantity: 250 mg - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - nelarabine is indicated for the treatment of patients with relapsing /refractory t-cell acute lymphoblastic leukaemia and t-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment.,due to the small patient populations in these disease settings, the information to support these indications is based on limited data..

European Union - English - EMA (European Medicines Agency)

sandoz pharmaceuticals d.d. - nelarabine - precursor t-cell lymphoblastic leukemia-lymphoma - antineoplastic agents - nelarabine is indicated for the treatment of patients with t-cell acute lymphoblastic leukaemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - nelarabine - solution for infusion - 5mg/1ml

Canada - English - Health Canada

sandoz canada incorporated - nelarabine - solution - 5mg - nelarabine 5mg - antineoplastic agents

Israel - English - Ministry of Health

novartis israel ltd - nelarabine - solution for infusion - nelarabine 5 mg/ml - purine analogues - atriance 5 mg/ml is indicated for the treatment of patients with t-cell acute lymphoblastic leukaemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

novartis pharma k.k. - nelarabine - injection

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sandoz k.k. - nelarabine - injection

United States - English - NLM (National Library of Medicine)

cipla ltd. - nevirapine (unii: 99dk7fvk1h) (nevirapine - unii:99dk7fvk1h) - nevirapine 200 mg - nevirapine is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv-1) infection in adults and pediatric patients 15 days and older [see clinical studies (14.1, 14.2] . limitations of use: based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine is not recommended to be initiated, unless the benefit outweighs the risk, in: -   adult females with cd4+ cell counts greater than 250 cells/mm3 or -   adult males with cd4+ cell counts greater than 400 cells/mm3 [see warnings and precautions (5.1)] . nevirapine tablets are contraindicated: - in patients with moderate or severe (child-pugh class b or c, respectively) hepatic impairment [see warnings and precautions (5.1) and use in specific populations (8.7)] - for use as part of occupational and non-occupational post-exposure prophylaxis (pep) regimens [see warnings and precautions (5.1)] . teratogenic effects pregnancy exposur